Bayer’s kidney disease drug Kerendia reduces cardiovascular risk by 16%
US will still pay at least twice as much after negotiating drug prices
Illumina wins Grail battle in blow to EU merger power
Novo Nordisk's Ozempic shortage expected to continue into Q4
*please scroll down for all the latest news*
